Eric Kmiec, Ph.D

Executive Director and Chief Scientific Officer, The Gene Editing Institute ChristianaCare

  • Wilmington DE

Dr. Kmiec, a pioneer in the field, has achieved several ground-breaking firsts in CRISPR gene editing.

Contact

ChristianaCare

View more experts managed by ChristianaCare

Spotlight

2 min

Kelly Banas, Ph.D., To Present Her Latest Discovery at CRISPR Medicine’s First International Conference

Global audience in Copenhagen, Denmark, will learn of Gene Editing Institute research targeting the NRF2 gene in cancer cells Kelly Banas, Ph.D., principal investigator at ChristianaCare’s Gene Editing Institute, will present her latest research discovery related to targeting the NRF2 gene in cancer cells at the first CRISPR Medicine Conference held in Copenhagen, Denmark, April 22 to 25. The Gene Editing Institute’s research has focused on the NRF2 gene and the strong immune response it causes within cancer cells, allowing them to grow resistant to chemotherapy and leading cancer treatments to fail. By disrupting the NRF2 gene in cancer cells while allowing healthy cells to continue producing it, chemotherapy treatment becomes more effective. Gene Editing Institute principal investigators Kelly Banas, Ph.D., and Natalia Rivera-Torres, Ph.D., in the lab. Banas’ latest research delves into the mechanism of DNA repair following the removal of NRF2, ensuring that surrounding DNA in healthy cells is not affected and that the repair does not produce an unexpected outcome. “I’m extremely honored to be invited to this conference to highlight the work that all of our researchers at the Gene Editing Institute have put into this study,” Banas said. “The work we have done to characterize the impact of CRISPR on the NRF2 gene has changed how we approach new cancer targets. “This has influenced how we design experiments and analyze our data,” she said, “so it’s got a big impact on not just our work, but the work of anyone we collaborate with in the future. This community is full of phenomenal voices, and we’re committed to sharing our work in contexts like this to continue building a foundation of CRISPR research that will uplift treatment for some of the deadliest and most resilient cancers and diseases.” Read about Banas’ earlier research here.

Eric Kmiec, Ph.DNatalia Rivera-Torres, Ph.D

2 min

Statement from Dr. Eric Kmiec About Expected FDA Approval for CRISPR-Driven Treatment for Sickle Cell Disease

Below is a statement from Eric Kmiec, Ph.D., founder and executive director, ChristinaCare Gene Editing Institute, regarding the expected approval by the Food and Drug Administration of exa-cel (Casgevy), the CRISPR-driven treatment for sickle cell disease and betta thalassemia. If you wish to interview Dr. Kmiec, please contact Mak Sisson, Makenzie.sisson@christinacare.org,302-623-5306 or Anna Chen, achen@burness.com, 215-262-7670. “As scientists, the fact that we have arrived at a potential curative treatment for sickle cell disease in a relatively brief period is a testament to the power of resolute researchers in this field who have never stopped. And the FDA’s expected approval comes with many firsts. For the first time we have what appears to be a safe and curative treatment for one of the most painful diseases that cuts life short. And it is remarkable that finally we are focusing on the Black population first, who are most affected by this disease. This priority is long, long overdue. The challenge, however, is the very people we want to help may not be able to get access to or afford the million-dollar treatment and the length of time it will take to be treated — weeks and weeks in the hospital. The numbers of people who can be treated are limited. We must work with the health care industry and pharmaceutical companies who will market produce and deliver the treatments to make sure that all people can get access. What can they do to make treatments more affordable and more available? What can they do to support continued research to assess the long-term effects this treatment may have? And how can we make this easier to deliver? As important as it is to have developed this new treatment, right now we must do our best to communicate well to the public what new findings like this mean. Take the time to explain it all. It cannot be oversold. We must make the communication about this first CRISPR-driven treatment as important as the science itself.” Eric B. Kmiec, Ph.D., is the founder and executive director of the Gene Editing Institute at ChristianaCare. He is also co-founder and chief scientific officer of CorriXR Therapeutics. Widely recognized for his pioneering work in the fields of molecular medicine and gene editing, Dr. Kmiec has developed CRISPR based genetic therapies for Sickle Cell Disease and Non-Small Cell Lung Cancer. He is Editor-in-Chief of the journal, Gene and Genome Editing.

Eric Kmiec, Ph.D

3 min

Gene Editing Institute Opens a Unique Learning Lab for High School and College Students

Free program uses CRISPR in a Box™ toolkit to teach the power of gene editing To inspire the next generation of students to pursue careers in STEM (science, technology, engineering and math) and learn about the power of genomic science, ChristianaCare’s Gene Editing Institute has launched a new Learning Lab on its premises that offers educational programming about revolutionary CRISPR gene editing technology. Located next to the Gene Editing Institute’s lab on the University of Delaware’s STAR Campus, the Learning Lab is a physical space that provides an immersive field trip experience for upper-level high school students and college undergraduates who may not have access at their schools to a laboratory to conduct gene editing experiments. There is no cost for schools to use the lab or for the materials to conduct the experiment. The Gene Editing Institute wants to ensure that all schools have equal opportunity to participate in educational programming at the lab. Students using the lab can perform a gene editing experiment in a single day using the Gene Editing Institute’s innovative CRISPR in a Box™ educational toolkit. All materials in the kit are safe, synthetic materials, and allow students to perform CRISPR gene editing with non-infectious E. coli bacteria. They will be able to see an appearance change indicating gene editing has occurred at the end of their experiment. “Students around the country, no matter where they go to school, have the potential to be scientists, researchers and laboratory technicians,” said Eric Kmiec, Ph.D., executive director and chief scientific officer of ChristianaCare’s Gene Editing Institute. “Our hope is that by creating access and space for students to explore, we can inspire the next generation of students to pursue STEM careers. The Learning Lab allows us to help cultivate the next generation of genetic scientists and strengthen Delaware and our region as a leader in biotechnology.” Education Program Manager Amanda Hewes, MS, developed the Learning Lab after noticing a problem that was undercutting the opportunities of teachers to bring gene editing experiments into the classroom — a lack of space and equipment. Amanda Hewes, education program coordinator, assists students from Wilmington Charter School with their samples of DNA during a Learning Lab experiment. “We don’t want anything to hinder the way students learn about CRISPR gene editing,” Hewes said. “If a student feels like there are too many steps, or a teacher doesn’t have an essential piece of equipment, then we’ve lost an opportunity to bring the next generation of scientists into the lab. We’re striving to break down as many barriers as possible for students.” Learning real-world applications of gene editing The Learning Lab also allows students to speak directly with experts in the field about careers in biotechnology and gene editing as they learn the difference between such things as phenotypic and genotypic readouts in their gene editing experiments. This gives students the chance to ask about the real-world application of genome experiments in a research lab. It also lets them think about their place in a lab setting. “I’ve never been in an actual lab setting before,” said Shiloh Lee, a junior at the Charter School of Wilmington, at a recent class. “I think it is very, very cool to be able to experience it.” “I’ve learned a lot of new skills with the micropipetting,” said Pauline Zhuang, a senior at The Charter School of Wilmington. “We don’t have the same resources at our school. The CRISPR in a Box is such a great resource. My classmates and I have been able to experience, firsthand, what it is like to actually do gene editing.” Through the program, the Gene Editing Institute hopes to educate 1,000 students by spring 2024. Currently, the lab is on track to engage more than 200 students by the end of the spring 2023 semester. CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats, which are the hallmark of a bacterial defense system that forms the basis for CRISPR-Cas 9 genome editing technology. The CRISPR technology enables researchers to modify genes in living cells and organisms and may make it possible to correct mutations at precise locations in the human genome in order to treat genetic causes of disease. For more information about the Learning Lab and the educational program, email geneeditinginstitute@christianacare.org.

Eric Kmiec, Ph.D
Show More +

Biography

Eric B. Kmiec, Ph.D., is the founder and executive director of the Gene Editing Institute at ChristianaCare. He is also co-founder and chief scientific officer of CorriXR Therapeutics. Widely recognized for his pioneering work in the fields of molecular medicine and gene editing, Dr. Kmiec has developed CRISPR based genetic therapies for Sickle Cell Disease and Non-Small Cell Lung Cancer. Dr. Kmiec holds faculty appointments at the University of Delaware and The Wistar Institute and has been an NIH and National Science Foundation supported principal investigator for 35 years. His laboratory has made major discoveries in the CRISPR/gene editing field, and he serves on numerous editorial boards, authoring 169 peer-reviewed publications and books. He has served as primary mentor for 18 doctoral students and numerous postdoctoral scholars.

He is Editor-in-Chief of the journal, Gene and Genome Editing.

Dr. Kmiec is an accomplished speaker in human gene editing and its social and ethical impacts. He has received numerous service medals and awards, including the Eminent Scholar at Marshall University, Proudford Award in Sickle Cell Disease, Bio-Science Innovation Awards and the Philadelphia Life Science Innovator Award.

Areas of Expertise

Gene Editing
Biomedical Research
Molecular Medicine

Education

University of Florida

Ph.D.

Molecular Biology / Biochemistry

1984

Southern Illinois University Edwardsville

M.S.

Cell Biology / Biochemistry

1980

Rutgers University

B.A.

Microbiology

1978

Media Appearances

Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair

EurekAlert! | The American Association for the Advancement of Science  online

2021-02-11

Wilmington, DE, Feb. 11, 2020 -Scientists have developed an affordable, downloadable app that scans for potential unintended mistakes when CRISPR is used to repair mutations that cause disease. The app reveals potentially risky DNA alterations that could impede efforts to safely use CRISPR to correct mutations in conditions like sickle cell disease and cystic fibrosis.

View More

New App Can Reveal Unintentional Mutations of a CRISPR Edit

CRISPR Medicine News  online

2021-02-15

A team of scientists from ChristianaCare's Gene Editing Institute in Delaware, US have developed a new customisable app that they say will make it much easier to find out what happened during a CRISPR experiment.

View More

Affordable CRISPR App Reveals Unintended Mutations At Site Of CRISPR Gene Repair

SCIENMAG  online

2021-02-11

Study in The CRISPR Journal reports the app advances CRISPR gene therapy R&D; 18-year-old software savant helped lead the app’s development

Wilmington, DE, Feb. 11, 2020 -Scientists have developed an affordable, downloadable app that scans for potential unintended mistakes when CRISPR is used to repair mutations that cause disease. The app reveals potentially risky DNA alterations that could impede efforts to safely use CRISPR to correct mutations in conditions like sickle cell disease and cystic fibrosis.

View More

Show All +

Selected Papers and Publications

Potential Inequities in New Medical Technologies

Scientific American

Eric B. Kmiec, Jonathan Marron

2020-03-28

As headline-catching new technologies emerge—like tools to “edit” our DNA—researchers, doctors, patients and the general public are excited about the future of medicine and the research that informs its practice. For some, there are obvious and critical conversations taking place about the ethics of this research, including how we do it (think “CRISPR babies” in China) and the potential for edits (intentional or otherwise) that could be passed on to future generations.

View more

Understanding the diversity of genetic outcomes from CRISPR-Cas generated homology-directed repair

Nature

Brett M. Sansbury, Amanda M. Hewes & Eric B. Kmiec

2019-12-06

As CRISPR-Cas systems advance toward clinical application, it is essential to identify all the outcomes of gene-editing activity in human cells. Reports highlighting the remarkable success of homology-directed repair (HDR) in the treatment of inherited diseases may inadvertently underreport the collateral activity of this remarkable technology.

View more

Deconvolution of Complex DNA Repair (DECODR): Establishing a Novel Deconvolution Algorithm for Comprehensive Analysis of CRISPR-Edited Sanger Sequencing Data

Mary Ann Liebert, Inc.

Kevin Bloh, Rohan Kanchana, Pawel Bialk, Kelly Banas, Zugui Zhang, Byung-Chun Yoo, and Eric B. Kmiec

2021-02-19

During CRISPR-directed gene editing, multiple gene repair mechanisms interact to produce a wide and largely unpredictable variety of sequence changes across an edited population of cells. Shortcomings inherent to previously available proposal-based insertion and deletion (indel) analysis software necessitated the development of a more comprehensive tool that could detect a larger range and variety of indels while maintaining the ease of use of tools currently available.

View more

Show All +

Social